The hexane fraction of Ardisia crispa Thunb. A. DC. roots inhibits inflammation-induced angiogenesis

BMC Complementary and Alternative Medicine

Yeong Looi Ting²  Che Norma Mat Taib¹  Latifah Saiful Yazan²  Roslida Abdul Hamid²  Dayang Erna Zulaikha Awang Hamsin³ 

[1] Department of Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, 43400, Malaysia;Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Selangor, 43400, Malaysia;Department of Paraclinical Science, Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, Kuching, Sarawak, 93150, Malaysia

关键词: Angiogenesis;    Murine air pouch granuloma;    Miles vascular permeability assay;    Ardisia crispa;   

Others  :  1231171
DOI  :  10.1186/1472-6882-13-5

 received in 2012-05-17, accepted in 2013-01-04,  发布年份 2013

【 摘 要 】

Background

Ardisia crispa (Myrsinaceae) is used in traditional Malay medicine to treat various ailments associated with inflammation, including rheumatism. The plant’s hexane fraction was previously shown to inhibit several diseases associated with inflammation. As there is a strong correlation between inflammation and angiogenesis, we conducted the present study to investigate the anti-angiogenic effects of the plant’s roots in animal models of inflammation-induced angiogenesis.

Methods

We first performed phytochemical screening and high-performance liquid chromatography (HPLC) fingerprinting of the hexane fraction of Ardisia crispa roots ethanolic extract (ACRH) and its quinone-rich fraction (QRF). The anti-inflammatory properties of ACRH and QRF were tested using the Miles vascular permeability assay and the murine air pouch granuloma model following oral administration at various doses.

Results

Preliminary phytochemical screening of ACRH revealed the presence of flavonoids, triterpenes, and tannins. The QRF was separated from ACRH (38.38% w/w) by column chromatography, and was isolated to yield a benzoquinonoid compound. The ACRH and QRF were quantified by HPLC. The LD₅₀ value of ACRH was 617.02 mg/kg. In the Miles vascular permeability assay, the lowest dose of ACRH (10 mg/kg) and all doses of QRF significantly reduced vascular endothelial growth factor (VEGF)-induced hyperpermeability, when compared with the vehicle control. In the murine air pouch granuloma model, ACRH and QRF both displayed significant and dose-dependent anti-inflammatory effects, without granuloma weight. ACRH and QRF significantly reduced the vascular index, but not granuloma tissue weight.

Conclusions

In conclusion, both ACRH and QRF showed potential anti-inflammatory properties in a model of inflammation-induced angiogenesis model, demonstrating their potential anti-angiogenic properties.

【 授权许可】

   
2013 Awang Hamsin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Woo AYH, Zhao Y, Zhang R, Zhou Z, Cheng CHK: Angiogenesis and Chinese medicinal foods. In Anti-angiogenic functional and medicinal foods. Edited by Losso JN, Shahidi F, Bagchi D. New York: CRC Press; 2007:581-592.
• [2]Folkman J: Tumor angiogenesis: therapeutic implications. New Engl J Med 1971, 285(21):1182-1186.
• [3]Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1):27-31.
• [4]Khurana R, Simmons M, Martin JF, Zachary IC: Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005, 112(12):1813-1824.
• [5]Nakano T, Nakashima Y, Yonemitsu Y, Sumiyoshi S, Chen YX, Akishima Y, Iida M, Sueishi K: Angiogenesis and lymphangiogenesis and the expression of lymphangiogenic factors in the atherosclerotic intima of human coronary arteries. Hum Pathol 2005, 36(4):330-340.
• [6]Chen F, Eriksson P, Kimura T, Herzfeld I, Valen G: Apoptosis and angiogenesis are induced in the unstable atherosclerotic plaque. Coron Artery Dis 2005, 16(3):191-197.
• [7]Hayden MR, Tyagi SC: Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol 2004, 3:1-6. BioMed Central Full Text
• [8]Walsh DA, Pearson CI: Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res Ther 2001, 3(3):147-153. BioMed Central Full Text
• [9]Weipeng B, Fei C, Ling B, Ping Z, Wenxin Q: Dihydrotanshinone I inhibits angiogenesis both in vitro and in vivo. Acta Biochim Biophys Sin 2008, 40:1-6.
• [10]Shishodia S, Sethi G, Aggrawal BB: Curcumin: getting back to the roots. Ann N Y Acad Sci 2005, 1056(1):206-217.
• [11]Raso GM, Meli R, Di Carlo G, Pacilio M, Di Carlo R: Inhibition of inducible NO synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A. Life Sci 2001, 68(8):921-931.
• [12]Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S: Inhibition of angiogenesis by humulone; a bitter acid from beer hop. Biochem Biophys Res Commun 2001, 289(1):220-224.
• [13]Kwon HJ, Shim JS, Kim JH, Cho HY, Yum YN, Kim SH, Yu J: Betulinic acid inhibits growth factor-induced angiogenesis via the modulation of mitochondrial function in endothelial cells. Jpn J Cancer Res 2002, 93(4):417-425.
• [14]Surh YJ: Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem Toxicol 2002, 40(8):1091-1097.
• [15]Bråkenhielm E, Cao R, Cao Y: Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001, 15(10):1798-1800.
• [16]Delmas D, Lançon A, Colin D, Jannin B, Latruffe N: Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 2006, 7(4):423-442.
• [17]Foitzik T, Hotz HG, Hotz B, Wittig F, Buhr HJ: Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Hepatogastroenterology 2003, 50(52):1159-1162.
• [18]Hoper MM, Voelkel NF, Bates TQ, Allard JD, Horan M, Shepherd D, Tudier R: Prostaglandin induce VEGF growth factor in human monocytic cell lines and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997, 17(6):748-756.
• [19]Romano M, Claria J: Cyclooxygenase-2 and 5-lipoxygenase converging function on cell proliferation and angiogenesis: implication for cancer therapy. FASEB J 2003, 17(14):1986-1995.
• [20]Heyne K: Tumbuhan berguna Indonesia III, translated by Badan Litbang Kehutanan Jakarta. Indonesia: Yayasan Sarana Wana Jaya; 1987.
• [21]Muhammad Z, Mustafa AM: Traditional Malay Medicinal Plants. Kuala Lumpur: Fajar Bakti; 1994:39-41.
• [22]Jansakul C, Herbert B, Lennart K, Gunnar S: Ardisiacrispin A and B, two utero-contacting saponins from Ardisia crispa. Planta Medica 1987, 53(5):405-409.
• [23]Yoshida K, Koma Y, Kikuchi H: Therapeutic substance FR-900359 from Ardisia crispa. Japan Kokkai Tokyo Kobo JP 1987, 283:917-920.
• [24]Kang YH, Kim WH, Park MK, Han BH: Antimetastatic and antitumor effects of benzoquuinonoid AC7-1 from Ardisia crispa. Int J Cancer 2001, 93(5):736-740.
• [25]Roslida AH, Teh YH, Kim KH: Evaluation of anti-ulcer activity of Ardisia crispa Thunb. D.C. PharmacognRes 2009, 1:250-255.
• [26]Roslida AH, Kim KH: Anti-inflammatory effect and anti-hyperalgesic effect of Ardisia crispa Thunb D C. Pharmacogn Mag 2008, 4:262-268.
• [27]Roslida AH: Anti-inflammatory and analgesic effects of AC-2 isolated from Ardisia crispa are mediated via COX-2 inhibition. Kuala Lumpur, Malaysia: PhD thesis, Universiti Malaya, Physiology Department; 2004.
• [28]Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD: The codependence of angiogenesis and chronic inflammation. FASEB J 1997, 11(6):457-465.
• [29]Wang W, Bergh A, Damber JE: Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005, 11(9):3250-3256.
• [30]Ghosh AK, Hirasawa N, Niki H, Ohuchi K: Cyclooxygenase-2 mediated angiogenesis in carageenin- induced granulation tissue in rats. J Pharmacol Exp Ther 2000, 295(2):802-809.
• [31]Form DM, Auerbach R: PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983, 172(2):214-218.
• [32]Stjernschantz J, Nilsson SFE, Astin M: Vasodynamic effects of eicosanoids in the eye. Prog Clin Biol Res 1989, 312:155-170.
• [33]Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ: Interleukin-6 induces the expression of vascular endothelial growth-factor. J Biol Chem 1996, 271(2):736-741.
• [34]Ben-Av P, Crofford LJ, Wilder RL, Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995, 372(1):82-87.
• [35]Folkman J, Brem H: Angiogenesis and inflammation. In Inflammation: basic principles and clinical correlates. 2nd edition. Edited by Gallin JI, Goldstein IM, Snyderman R. New York: Raven; 1992:821-839.
• [36]Ayoola GA, Coker HAB, Adesegun SA, Adepoju-Bello AA, Obaweya K, Ezannia EC, Atangbayila TO: Phytochemical screening and antioxidant activites of some selected medicinal plants used for malaria therapy in southwestern Nigeria. Trop J Pharm Res 2008, 7(3):1019-1024.
• [37]Shelar R, Maurya C, Tekale P, Katkar K, Naik V, Suthar A, Chauhan VS: Embelin - An HPLC Method for Quantitative Estimation in Embelia ribes Burm. F: Int J Pharm Clin Res 2009, 1(3):146-149.
• [38]Veerappan A, Miyazaki S, Kadarkaraisamy M, Ranganathan D: Acute and subacute toxicity studies of Aegle marmelos Corr., an Indian medicinal plant. Phytomedicine 2007, 14(2–3):209-215.
• [39]Pakhneshan P, Birsner AE, Adini I, Becker CM, D’Amato R: Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs. Invest Ophthalmol Vis Sci 2008, 49(9):3909-3913.
• [40]Wang C, Duan H, He L: Inhibitory effect of atractylenoline I on angiogenesis in chronic inflammation in vivo and in vitro. Eur J Pharmacol 2009, 612(1–3):143-152.
• [41]Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacologcal effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinasem in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 1998, 284(2):687-692.
• [42]Gonzalez de Mejia E, Ramirez-Mares MV: Ardisia: health-promoting properties and toxicity of phytochemicals and extracts. Toxicol Mech Methods 2011, 21(9):667-674.
• [43]Fukuyama Y, Kiriyama Y, Okino J, Kodama M, Iwaki H, Hosozawa S: Naturally occurring 5-lipoxygenase inhibitor. II. Structures and syntheses of ardisianones A and B, and maesanin, alkenyl-1, 4-benzoquinones from the rhizome of Ardisia japonica. Chem Pharm Bull 1993, 41(3):561-565.
• [44]Fukuyama Y, Kiriyama Y, Okino J, Kodama M, Iwaki H, Hosozawa S: Total synthesis of ardisiaquinone A, a potent 5-lipoxygenase inhibitor, isolated from Ardisia sieboldii, and degree of 5-lipoxygenase inhibitory activity of its derivatives. Chem Pharm Bull 1994, 42(10):2211-2213.
• [45]Chang HS, Lin YJ, Lee SJ, Yang CW, Lin WY, Tsai IL, Chen IS: Cytotoxic alkyl benzoquinones and alkyl phenols from Ardisia virens. Phytochemistry 2009, 70(17–18):2064-2071.
• [46]Ong CY, Ling SK, Ali RM, Chee CF, Samah ZA, Ho AS, Teo SH, Lee HB: Systematic analysis of in vitro photo-cytotoxic activity to extracts from terrestrial plants in Peninsula Malaysia for photodynamic therapy. J Photochem Photobiol 2009, 96(3):216-222.
• [47]Knighton D, Asprunk D, Tapper D: Avascular and vascular phase of tumor growth in the chick embryo. Br J Cancer 1977, 35(3):347-356.
• [48]Gimbrone MA Jr, Cotran RS, Leapman SB, Folkman J: Tumor growth and neovascularization, an experimental model using rabbit cornea. J Natl Cancer Inst 1974, 52(2):413-427.
• [49]Zhang J, Sun Y, Zhang JQ, Ramires FJ, Weber KT: Appearance and regression of rat air pouch tissue. J Mol Cell Cardiol 1999, 31(5):1005-1013.
• [50]Verheul HM, Panigrahy D, Yuan J, D’Amato RJ: Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 1999, 79(1):114-118.
• [51]Senger DR, Van deWater L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF: Vascular permeability factor (VPF/VEGF) in tumor biology. Cancer Metastasis Rev 1993, 12(3–4):303-324.
• [52]Jennifer AD, Jennifer EH, Gerald EH: Role of apoptosis in anti-angiogenic cancer therapies. In Apoptosis, Senescence and Cancer. Edited by Gewirtz DA, Holt SE, Grant S. New Jersey: Humana Press Inc; 2007:537-556.
• [53]Chiarugi V, Magnelli L, Gallo O: COX-2, iNOS and p53 as play-makers of tumor angiogenesis. Int J Mol Med 1998, 2(6):715-719.
• [54]Vasile E, Qu-Hong , Dvorak HF, Dvorak AM: Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cell cultured with VPF/VEGF on floating matrigel-collagen gel. J Histochem Cytochem 1999, 47(2):159-167.
• [55]Funk CD: Prostaglandins and leukotrienes: Advances in eicosanoids biology. Science 2001, 294(5548):1871-1875.
• [56]Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM: Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998, 97(1):99-107.
• [57]Leahy KM, Koki AT, Masferrer JL: Role of Cyclooxygenases in Angiogenesis. Curr Med Chem 2000, 7(11):1163-1170.
• [58]Colville-Nash PR, Alam CA, Appleton I, Browne JR, Seed MP, Willoughby DA: The pharmacological modulation of angiogenesis in chronic granulomatous inflammation. J Pharmacol Exp Ther 1995, 274(3):1463-1472.
• [59]Gilroy DW, Tomlinson A, Willoughby DA: Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflamm Res 1998, 47(2):79-85.
• [60]Qu Z, Huang XN, Ahmadi P, Andresevic J, Planck SR, Hart CE, Rosenbaum JT: Expression of basic fibroblast growth factor in synovial tissue from patients with rheumatoid arthritis and degenerative joint disease. Lab Invest 1995, 73(3):339-346.
• [61]Remmers EF, Sano H, Wilder RL: Platelet-derived growth factors and heparin binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991, 21(3):191-199.
• [62]Hua H, Feng L, Zhang XP, Zhang LF, Jin J: Anti-angiogenic activity of julibroside J8, a natural product isolated from Albizia julibrissin. Phytomedicine 1999, 16(8):703-711.